E Fund Management Co. Ltd. Has $524,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

E Fund Management Co. Ltd. raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 5.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,832 shares of the biotechnology company’s stock after acquiring an additional 1,150 shares during the period. E Fund Management Co. Ltd.’s holdings in Exelixis were worth $524,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of EXEL. Alaska Permanent Fund Corp increased its position in shares of Exelixis by 1.5% in the third quarter. Alaska Permanent Fund Corp now owns 40,855 shares of the biotechnology company’s stock worth $893,000 after purchasing an additional 596 shares during the period. Fifth Third Bancorp grew its stake in Exelixis by 44.2% during the third quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock worth $43,000 after buying an additional 604 shares in the last quarter. Signaturefd LLC increased its holdings in Exelixis by 17.1% in the 3rd quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 668 shares during the period. Fisher Asset Management LLC raised its position in shares of Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 728 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its holdings in shares of Exelixis by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company’s stock worth $3,176,000 after acquiring an additional 738 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Exelixis Trading Down 2.5 %

NASDAQ:EXEL traded down $0.56 during trading hours on Wednesday, hitting $21.59. 2,209,821 shares of the company were exchanged, compared to its average volume of 2,322,132. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of 33.73, a price-to-earnings-growth ratio of 0.59 and a beta of 0.57. Exelixis, Inc. has a one year low of $18.52 and a one year high of $24.34. The company has a fifty day simple moving average of $22.98 and a 200 day simple moving average of $22.24.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.16). The company had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The company’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.12 EPS. Equities research analysts predict that Exelixis, Inc. will post 1.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Alan M. Garber sold 19,205 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the sale, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Exelixis news, Director David Edward Johnson bought 190,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was acquired at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the purchase, the director now directly owns 1,100,730 shares of the company’s stock, valued at approximately $22,785,111. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan M. Garber sold 19,205 shares of the business’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the transaction, the director now owns 35,703 shares in the company, valued at approximately $857,229.03. The disclosure for this sale can be found here. Company insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EXEL. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Exelixis in a research report on Friday, May 3rd. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a report on Monday, March 18th. TD Cowen raised their price target on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Finally, Barclays cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective for the company. in a research report on Thursday, April 11th. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $26.33.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.